Azaya Launches New CDMO

Parexo Labs, a division of Azaya, launches as a new CDMO with an emphasis on nanotechnology and liposomal manufacturing.
Jul 09, 2013
By PharmTech Editors

Azaya Therapeutics, a biopharmaceutical company focused on focused on developing cancer treatments through its nanotechnology platform, announced the launch of a new division, Parexo Labs, as a CDMO providing chemical testing and liposomal manufacturing services to outside organizations. Parexo Labs will offer capabilities in cytotoxic and nanoparticle analysis and liposome manufacturing, including proprietary analytical methodology to detail release rates and characterization attributes of nanoparticles.

“Azaya Therapeutics has over 10 years of experience in the cytotoxic and nanotechnology arenas, which we are now leveraging with the rollout of Parexo Labs,” said Mike Dwyer, Azaya Therapeutics CEO and president, in a company press release. “Through Parexo, we can apply these analytical capabilities and development methodologies to organizations in need of them for their own development programs.”


Parexo Labs services cover method development and validation for cytotoxics, as well as raw material testing, stability storage and testing, chemical characterization and other analyses. Parexo also provides customized liposome manufacturing services, based on its proprietary nanoparticle release methodology.